Immunological Responses in Septic Conditions

Sepsis arises when infection triggers a dysregulated host response, characterised initially by an overwhelming release of pro-inflammatory mediators commonly termed a cytokine storm. This hyperinflammatory phase engages innate immune cells such as neutrophils and monocytes, promoting pathogen clearance but also collateral tissue injury. Almost concurrently, a compensatory anti-inflammatory response emerges, downregulating antigen presentation and effector functions in monocytes and lymphocytes. Prolonged or excessive anti-inflammatory signalling leads to immunoparalysis, in which host defences are blunted, increasing susceptibility to secondary infections and poor outcomes. Key mechanisms include reduced expression of human leucocyte antigen-DR on monocytes, exhaustion of T-cell subsets, shifts in macrophage polarisation and metabolic reprogramming of innate cells. Recent advances employ high-resolution profiling—single-cell transcriptomics and immune-functional assays—to delineate monocyte heterogeneity, identify biomarkers of immune status and stratify patients for precision therapy. Interventions under investigation aim either to temper excessive inflammation in the early phase or to restore immune competence in later stages, using cytokine-based nanotherapies or growth factors such as granulocyte-macrophage colony-stimulating factor. Understanding the dynamic interplay between pro- and anti-inflammatory pathways is central to reducing the global burden of sepsis and improving patient survival.

Research from Nature Portfolio

Recent studies have demonstrated that a lipid-based nanoparticle delivery system carrying interleukin-4 can target myeloid progenitor niches in spleen and bone marrow, inducing a trained immunity programme. In models of lipopolysaccharide-induced hyperinflammation, this approach both restricts acute inflammatory injury and reprogrammes monocytes to resist immunoparalysis. Ex vivo assays using human sepsis samples confirmed that interleukin-4 nanotherapy enhances cytokine responsiveness and restores antigen-presenting capacity, laying groundwork for translational development of targeted immunorestorative treatments.

Immunological Responses in Septic Conditions publication trend

The graph below shows the total number of articles in immunological responses in septic conditions across all publications each year (not limited to Nature Index journals).

Technical terms

Immunoparalysis: A phase of impaired immune function following hyperinflammation, marked by reduced antigen presentation and cytokine responses.

Trained immunity: Long-term enhancement of innate cell responsiveness induced by specific stimuli, leading to a heightened state of alert.

HLA-DR: A major histocompatibility complex class II protein on antigen-presenting cells, essential for T-cell activation.

Nanoparticle: A nanoscale carrier engineered to deliver therapeutic molecules selectively to target tissues or cells.

Monocyte: A circulating innate immune cell that differentiates into macrophages or dendritic cells and orchestrates inflammatory responses.

References

1. Single-cell transcriptome profiling of sepsis identifies HLA-DRlowS100Ahigh monocytes with immunosuppressive function. Military Medical Research (2023).
2. Resolving sepsis-induced immunoparalysis via trained immunity by targeting interleukin-4 to myeloid cells. Nature Biomedical Engineering (2023).
3. Utility of monocyte HLA-DR and rationale for therapeutic GM-CSF in sepsis immunoparalysis. Frontiers in Immunology (2023).